Does the Sleep Peptide DSIP Actually Help Chronic Insomnia? A Double-Blind Trial Says Probably Not

Double-blind, matched-pairs, parallel-groups design. 16 chronic insomnia patients spent 5 consecutive nights in a sleep lab. Night 1 was adaptation, night 2 was baseline. Before nights 3-5, half received IV DSIP (25 nmol/kg) and half received glucose placebo. Polysomnography measured objective sleep architecture, and subjective sleep quality and tiredness were also assessed.

DSIP was one of the earliest peptides investigated as a potential sleep aid, generating significant excitement when it was first identified in the 1970s. This was one of the few properly controlled human trials testing whether DSIP actually improves sleep. The largely negative result was important for the field — it tempered expectations about DSIP as a therapeutic peptide and highlighted the gap between a peptide's name/theoretical function and its actual clinical utility.

DSIP represented an early hope that peptide neuroscience could yield better sleep drugs. This negative result is part of a pattern — many neuropeptides that showed promise in animal models failed to deliver robust effects in human clinical settings. Despite this, sleep-related peptide research has continued and evolved, with the discovery of the orexin/hypocretin system eventually leading to successful insomnia drugs (suvorexant, lemborexant) that target neuropeptide receptors.

Very small sample size (n=16, only 8 per group). Only 3 treatment nights — too short to assess sustained effects. IV administration is impractical for real-world insomnia treatment. The statistically significant findings were weak and potentially driven by placebo group changes rather than true DSIP effects. Published in 1992 with older statistical methods.